Johnson & Johnson (JNJ)vsRevvity Inc. (RVTY)
JNJ
Johnson & Johnson
$232.77
-2.48%
HEALTHCARE · Cap: $567.28B
RVTY
Revvity Inc.
$98.37
-3.94%
HEALTHCARE · Cap: $11.62B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 3220% more annual revenue ($96.36B vs $2.90B). JNJ leads profitability with a 21.8% profit margin vs 8.3%. RVTY appears more attractively valued with a PEG of 0.64. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
RVTY
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-67.8%
Fair Value
$136.12
Current Price
$232.77
$96.65 premium
Intrinsic value data unavailable for RVTY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
3.5% earnings growth
ROE of 3.4% — below average capital efficiency
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : RVTY
The strongest argument for RVTY centers on PEG Ratio, Price/Book. PEG of 0.64 suggests the stock is reasonably priced for its growth.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : RVTY
The primary concerns for RVTY are EPS Growth, Return on Equity, P/E Ratio. A P/E of 50.1x leaves little room for execution misses.
Key Dynamics to Monitor
JNJ profiles as a mature stock while RVTY is a value play — different risk/reward profiles.
RVTY carries more volatility with a beta of 1.11 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 54/100), backed by strong 21.8% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Revvity Inc.
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets globally. The company is headquartered in Waltham, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?